OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Glucagon Regulation of Energy Expenditure
Maximilian Kleinert, Stephan Sachs, Kirk M. Habegger, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 21, pp. 5407-5407
Open Access | Times Cited: 109
Maximilian Kleinert, Stephan Sachs, Kirk M. Habegger, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 21, pp. 5407-5407
Open Access | Times Cited: 109
Showing 26-50 of 109 citing articles:
Glucagon agonism in the treatment of metabolic diseases including type 2 diabetes mellitus and obesity
Jonathan Brix Winther, Jens J. Holst
Diabetes Obesity and Metabolism (2024)
Open Access | Times Cited: 10
Jonathan Brix Winther, Jens J. Holst
Diabetes Obesity and Metabolism (2024)
Open Access | Times Cited: 10
Unlocking the Multifaceted Roles of GLP-1: Physiological Functions and Therapeutic Potential.
Tohada M. AL‐Noshokaty, Rehab Abdelhamid, Nourhan M. Abdelmaksoud, et al.
Toxicology Reports (2025) Vol. 14, pp. 101895-101895
Open Access | Times Cited: 1
Tohada M. AL‐Noshokaty, Rehab Abdelhamid, Nourhan M. Abdelmaksoud, et al.
Toxicology Reports (2025) Vol. 14, pp. 101895-101895
Open Access | Times Cited: 1
Short-term effects of high-protein, lower-carbohydrate ultra-processed foods on human energy balance
Franziska A. Hägele, Catrin Herpich, J. Koop, et al.
Nature Metabolism (2025)
Open Access | Times Cited: 1
Franziska A. Hägele, Catrin Herpich, J. Koop, et al.
Nature Metabolism (2025)
Open Access | Times Cited: 1
Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss
Allison B. Reiss, Shelly Gulkarov, Raymond Lau, et al.
Biomolecules (2025) Vol. 15, Iss. 3, pp. 408-408
Open Access | Times Cited: 1
Allison B. Reiss, Shelly Gulkarov, Raymond Lau, et al.
Biomolecules (2025) Vol. 15, Iss. 3, pp. 408-408
Open Access | Times Cited: 1
Pancreatic α-cells – The unsung heroes in islet function
Anna Wendt, Lena Eliasson
Seminars in Cell and Developmental Biology (2020) Vol. 103, pp. 41-50
Open Access | Times Cited: 56
Anna Wendt, Lena Eliasson
Seminars in Cell and Developmental Biology (2020) Vol. 103, pp. 41-50
Open Access | Times Cited: 56
Glucagon's Metabolic Action in Health and Disease
Anja Zeigerer, Revathi Sekar, Maximilian Kleinert, et al.
Comprehensive physiology (2021), pp. 1759-1783
Open Access | Times Cited: 54
Anja Zeigerer, Revathi Sekar, Maximilian Kleinert, et al.
Comprehensive physiology (2021), pp. 1759-1783
Open Access | Times Cited: 54
When fat meets the gut—focus on intestinal lipid handling in metabolic health and disease
Magdalena Wit, Jonathan Trujillo Viera, Akim Strohmeyer, et al.
EMBO Molecular Medicine (2022) Vol. 14, Iss. 5
Open Access | Times Cited: 32
Magdalena Wit, Jonathan Trujillo Viera, Akim Strohmeyer, et al.
EMBO Molecular Medicine (2022) Vol. 14, Iss. 5
Open Access | Times Cited: 32
Glucagon, from past to present: a century of intensive research and controversies
André Scheen, Pierre J. Lefèbvre
The Lancet Diabetes & Endocrinology (2022) Vol. 11, Iss. 2, pp. 129-138
Closed Access | Times Cited: 30
André Scheen, Pierre J. Lefèbvre
The Lancet Diabetes & Endocrinology (2022) Vol. 11, Iss. 2, pp. 129-138
Closed Access | Times Cited: 30
360-Degree Perspectives on Obesity
Magdalena Cuciureanu, Cătălin-Cezar Caratașu, Levon Gabrielian, et al.
Medicina (2023) Vol. 59, Iss. 6, pp. 1119-1119
Open Access | Times Cited: 22
Magdalena Cuciureanu, Cătălin-Cezar Caratașu, Levon Gabrielian, et al.
Medicina (2023) Vol. 59, Iss. 6, pp. 1119-1119
Open Access | Times Cited: 22
Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)
Albert Do, Frhaan Zahrawi, Wajahat Z. Mehal
Nature Reviews Drug Discovery (2024)
Closed Access | Times Cited: 7
Albert Do, Frhaan Zahrawi, Wajahat Z. Mehal
Nature Reviews Drug Discovery (2024)
Closed Access | Times Cited: 7
The Function of Gastrointestinal Hormones in Obesity—Implications for the Regulation of Energy Intake
Mona Farhadipour, Inge Depoortere
Nutrients (2021) Vol. 13, Iss. 6, pp. 1839-1839
Open Access | Times Cited: 36
Mona Farhadipour, Inge Depoortere
Nutrients (2021) Vol. 13, Iss. 6, pp. 1839-1839
Open Access | Times Cited: 36
Neonatal exposure to a wild-derived microbiome protects mice against diet-induced obesity
Benedikt Hild, Matthew S. Dreier, Ji Hoon Oh, et al.
Nature Metabolism (2021) Vol. 3, Iss. 8, pp. 1042-1057
Open Access | Times Cited: 36
Benedikt Hild, Matthew S. Dreier, Ji Hoon Oh, et al.
Nature Metabolism (2021) Vol. 3, Iss. 8, pp. 1042-1057
Open Access | Times Cited: 36
Preclinical evaluation of a protracted GLP-1/glucagon receptor co-agonist: Translational difficulties and pitfalls
Lotte Simonsen, Jesper Lau, Thomas Kruse, et al.
PLoS ONE (2022) Vol. 17, Iss. 3, pp. e0264974-e0264974
Open Access | Times Cited: 25
Lotte Simonsen, Jesper Lau, Thomas Kruse, et al.
PLoS ONE (2022) Vol. 17, Iss. 3, pp. e0264974-e0264974
Open Access | Times Cited: 25
Efficacy and safety of high‐dose glucagon‐like peptide‐1, glucagon‐like peptide‐1/glucose‐dependent insulinotropic peptide, and glucagon‐like peptide‐1/glucagon receptor agonists in type 2 diabetes
Christophe De Block, Eveline Dirinck, Ann Verhaegen, et al.
Diabetes Obesity and Metabolism (2022) Vol. 24, Iss. 5, pp. 788-805
Closed Access | Times Cited: 23
Christophe De Block, Eveline Dirinck, Ann Verhaegen, et al.
Diabetes Obesity and Metabolism (2022) Vol. 24, Iss. 5, pp. 788-805
Closed Access | Times Cited: 23
Glucagon augments the secretion of FGF21 and GDF15 in MASLD by indirect mechanisms
Michael M. Richter, I Kemp, Sara Heebøll, et al.
Metabolism (2024) Vol. 156, pp. 155915-155915
Open Access | Times Cited: 6
Michael M. Richter, I Kemp, Sara Heebøll, et al.
Metabolism (2024) Vol. 156, pp. 155915-155915
Open Access | Times Cited: 6
Pre-operative Predictors of Weight Loss and Weight Regain Following Roux-en-Y Gastric Bypass Surgery: a Prospective Human Study
Hassan Aliakbarian, Hina Y. Bhutta, Keyvan Heshmati, et al.
Obesity Surgery (2020) Vol. 30, Iss. 12, pp. 4852-4859
Closed Access | Times Cited: 38
Hassan Aliakbarian, Hina Y. Bhutta, Keyvan Heshmati, et al.
Obesity Surgery (2020) Vol. 30, Iss. 12, pp. 4852-4859
Closed Access | Times Cited: 38
Hypoaminoacidemia underpins glucagon-mediated energy expenditure and weight loss
David C. D. Hope, Charlotte E. Hinds, Tatiana Lopes, et al.
Cell Reports Medicine (2022) Vol. 3, Iss. 11, pp. 100810-100810
Open Access | Times Cited: 22
David C. D. Hope, Charlotte E. Hinds, Tatiana Lopes, et al.
Cell Reports Medicine (2022) Vol. 3, Iss. 11, pp. 100810-100810
Open Access | Times Cited: 22
Is Glucagon Receptor Activation the Thermogenic Solution for Treating Obesity?
Ellen Conceição-Furber, Tamer Coşkun, Kyle W. Sloop, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 21
Ellen Conceição-Furber, Tamer Coşkun, Kyle W. Sloop, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 21
Mechanisms of action of incretin receptor based dual- and tri-agonists in pancreatic islets
Franco Folli, Giovanna Finzi, Roberto Manfrini, et al.
AJP Endocrinology and Metabolism (2023) Vol. 325, Iss. 5, pp. E595-E609
Open Access | Times Cited: 12
Franco Folli, Giovanna Finzi, Roberto Manfrini, et al.
AJP Endocrinology and Metabolism (2023) Vol. 325, Iss. 5, pp. E595-E609
Open Access | Times Cited: 12
Dual glucagon‐like peptide ‐1 and glucagon receptor agonism reduces energy intake in type 2 diabetes with obesity
Rajna Golubić, Jane Kennet, Victoria Parker, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 7, pp. 2634-2644
Open Access | Times Cited: 4
Rajna Golubić, Jane Kennet, Victoria Parker, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 7, pp. 2634-2644
Open Access | Times Cited: 4
Insights into incretin-based therapies for treatment of diabetic dyslipidemia
Kerstin Stemmer, Brian Finan, Richard D. DiMarchi, et al.
Advanced Drug Delivery Reviews (2020) Vol. 159, pp. 34-53
Closed Access | Times Cited: 32
Kerstin Stemmer, Brian Finan, Richard D. DiMarchi, et al.
Advanced Drug Delivery Reviews (2020) Vol. 159, pp. 34-53
Closed Access | Times Cited: 32
Glucagon and energy expenditure; Revisiting amino acid metabolism and implications for weight loss therapy
David C. D. Hope, Tricia Tan
Peptides (2023) Vol. 162, pp. 170962-170962
Closed Access | Times Cited: 11
David C. D. Hope, Tricia Tan
Peptides (2023) Vol. 162, pp. 170962-170962
Closed Access | Times Cited: 11
Perspectives in weight control in diabetes – Survodutide
Thomas Klein, Robert Augustin, Anita M. Hennige
Diabetes Research and Clinical Practice (2023) Vol. 207, pp. 110779-110779
Closed Access | Times Cited: 10
Thomas Klein, Robert Augustin, Anita M. Hennige
Diabetes Research and Clinical Practice (2023) Vol. 207, pp. 110779-110779
Closed Access | Times Cited: 10
Novel pharmacotherapies for weight loss: Understanding the role of incretins to enable weight loss and improved health outcomes
Thomas Först, Christophe De Block, Stefano Del Prato, et al.
Diabetes Obesity and Metabolism (2025)
Closed Access
Thomas Först, Christophe De Block, Stefano Del Prato, et al.
Diabetes Obesity and Metabolism (2025)
Closed Access
Pharmacokinetic‐pharmacodynamic (PK/PD) modelling of cotadutide effect in patients with chronic kidney disease and type 2 diabetes mellitus
Hongtao Yu, Victoria Parker, Viknesh Selvarajah, et al.
British Journal of Clinical Pharmacology (2025)
Closed Access
Hongtao Yu, Victoria Parker, Viknesh Selvarajah, et al.
British Journal of Clinical Pharmacology (2025)
Closed Access
